Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T
A gene editing player hailing from Beijing has clinched $67 million to steer two of its lead candidates into the clinic — and to prove itself …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
